Gyre Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for organ fibrosis and inflammatory diseases. The company operates through its majority indirectly owned subsidiary, Gyre Pharmaceuticals, in the People's Republic of China, and through U.S. operations in San Diego, California. Its commercial portfolio includes ETUARY (pirfenidone) for idiopathic pulmonary fibrosis, Etorel (nintedanib) for pulmonary fibrosis and related interstitial lung diseases, and Contiva (avatrombopag) for thrombocytopenia associated with chronic liver disease and chronic idiopathic thrombocytopenia. The company is advancing its lead product candidate, Hydronidone, for the treatment of liver fibrosis associated with chronic hepatitis B in China and metabolic dysfunction-associated steatohepatitis in the United States. Gyre Therapeutics also holds a wholly-owned subsidiary, Cullgen Inc., which develops targeted protein degrader and degrader-antibody conjugate therapies for cancer and inflammatory diseases.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage gyretx.com
Sector Healthcare IR page ir.gyretx.com
Tags
organ fibrosis, pulmonary fibrosis, liver fibrosis, small-molecule therapeutics, targeted protein degraders, degrader-antibody conjugates, inflammatory diseases, hematology, idiopathic pulmonary fibrosis, metabolic dysfunction-associated steatohepatitis, Gyre Pharmaceuticals, ETUARY, Etorel, Contiva, Hydronidone, F351, Cullgen Inc.
Press page —

Metrics

Valuation  
Market cap $ 784.813M
Market cap (USD) $ 784.813M
P/E -27.15
PEG —
P/BV 7.27
P/S 6.45
P/OCF -33.89
P/FCF -31.75
Dividend yield 3.3%
Turnover / mcap —
Returns  
ROE 11.7%
ROI 14.3%
ROIC 11.4%
Profit margin 8.5%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 34
Quality score -22.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005
Revenue 116.588M 105.757M 113.45M 102.29M 7.338M 20.9M — 6K — — — 275K 3.629M 57.86M 97.637M 85.713M 25.062M 20.085M 11.576M — —
Net profit 9.88M 17.898M -85.48M -8.242M -87.933M -56.2M -55.178M -30.055M -21.561M -16.945M -14.762M -32.623M -46.705M -6.998M -8.529M 10.899M -39.404M -25.661M -28.073M 2.097M -28.992M
Free cash flow -180K -5.956M 17.375M 5.679M 12.303M — -43.677M -28.929M -19.963M -18.94M -19.39M -34.487M -40.704M -64.572M -85.149M 134.987M -24.471M -30.314M 19.894M -10.968M -26.497M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005
Share price 7.06 12.1 25.69 — — — — — — — — — — — — — — — — — —
Price performance 12m -0.42 -0.53 — — — — — — — — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — 15M 3.31M 1.82M 17.1M 15.6M 19.6M 31.1M
↳ YoY growth -77.9% -45.1% +842.6% -9.2% +26.0% +58.7%
↳ 5y CAGR +154.3% +5.5% +56.5%
Lease liabilities (USD) — — — 1.8M 1.64M 2.39M 38,000 409,000 1.6M 939,000
Cash and deposits (USD) 10.3M 14.5M 31.2M 15.4M 30.4M 44.3M 21.7M 33.5M 11.8M 37.1M
Intangible assets (USD) — — — — — — 297,000 205,000 273,000 4.73M
Right-of-use assets (USD) — — — 1.93M 1.83M 2.74M 66,000 489,000 1.82M 1.13M
Cash flow detail
Operating cash flow (USD) -18.5M -19.9M -28.6M -43.6M -55M -83.8M -33.1M 25.9M -3.64M 1.01M
Purchases of property, plant and equipment (USD) -468,000 -23,000 -376,000 -64,000 — -839,000 -4.99M -8.52M -2.32M -1.19M
Purchases of intangible assets (USD) — — — — — — -13,000 -69,000 -813,000 -733,000
Change in receivables (cash effect) (USD) 461,000 7,000 — -15M 11.7M 1.5M — 285,000 -5.26M -10.8M
Change in inventories (cash effect) (USD) — — — — — — -879,000 1.75M -2.14M -3.63M
Change in payables (cash effect) (USD) -102,000 -90,000 500,000 3.03M 1.65M 500,000 -6.23M 192,000 -245,000 13,000
Dividends paid (cash effect) (USD) — — — — — — -45M — — —
Income taxes paid (cash effect) (USD) — — — — — — -6.31M -6.35M -8.52M -5.62M
Share-based compensation (USD) 635,000 863,000 2.61M 3.2M 3.63M 3.41M 1.34M 7.28M 831,000 7.16M
Operating cash flow before change in receivables (USD) -18.9M -19.9M — -28.6M -66.7M -85.3M — 25.6M 1.62M 11.8M
Free cash flow (OCF - PPE - intangibles) (USD) -18.9M -20M -28.9M -43.7M — -84.6M 5.68M 17.3M -6.77M -913,000
Income detail
Research and development expense (USD) 11.6M 12.8M 21.5M 43.9M 53M 68.9M 13M 13.8M 12M 13.7M
↳ 5y CAGR -34.4% -23.5% -11.2% +17.6% +54.8% +42.9% +0.3% -8.5% -22.8% -23.7%
Total comprehensive income (USD) -16.9M -21.6M -30.1M -55.1M -56.3M -87.9M -8.24M -87M 16.4M 12.5M
Comprehensive income to owners (USD) -16.9M -21.6M -30.1M -55.1M -56.3M -87.9M -8.24M -93.8M 11.1M 6.85M
Provision for credit losses (USD) — — — — — — 200,000 — — —
Credit cost ratio (credit losses / average receivables) (%) — — — — — — 2.1% — — —
Reported Mar 8, 2017 Mar 19, 2018 Mar 8, 2019 Feb 20, 2020 Mar 4, 2021 Mar 30, 2023 Mar 27, 2024 Mar 17, 2025 Mar 17, 2025 Mar 13, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed

SAN DIEGO, November 5, 2026 -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (Nasdaq: GYRE), a U.S. biopharmaceutical company with research operations and commercial business in China to advance global development of protein degrader therapeutics, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.

Dr. Ying Luo, President and Chief Executive Officer of Gyre Therapeutics, commented, “I am pleased with our execution in the third quarter, our first full quarter incorporating Cullgen's operations within Gyre Therapeutics. We are advancing our protein degrader pipeline toward first-in-human data and initiating new clinical programs next year. Meanwhile, after recently completing an onsite inspection by China’s National Medical Products Administration, or NMPA, we continue to prepare for the China NMPA decision on F351 for CHB-induced liver fibrosis, which we anticipate launching, if approved, sometime in the first half of 2027.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 16, 2026, Gyre Therapeutics, Inc. (“Gyre”) entered into an employment agreement with Ying Luo, Ph.D. (the “Luo Employment Agreement”), to continue to serve as Gyre’s Chief Executive Officer. The Luo Employment Agreement provides for Dr. Luo’s at-will employment and an annual base salary of $500,000, an annual bonus to be determined annually by the Board of Directors of Gyre (the “Board”) or the Compensation Committee of the Board (the “Compensation Committee”) targeted at $150,000 for 2026, as well as his ability to participate in Gyre’s employee benefit plans generally. In the event of the termination of Dr. Luo’s employment by Gyre without “Cause” or by Dr. Luo for “Good Reason” (as each such term is defined in the Luo Employment Agreement), subject to Dr. Luo’s execution without revocation of a release of claims against Gyre and its subsidiaries, Dr. Luo will be entitled to: (i) an amount equal to Dr.

September 3, 2026

PDF Version

SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today announced that Company management will participate in the Cantor Global Healthcare Conference and the Morgan Stanley Healthcare Conference, both being held this month in New York, NY. Information about both conferences is below:

Cantor Global Healthcare Conference **Date:**Wednesday, September 9, 2026 **Time:**9:45 a.m. ET **Format:**Fireside chat

Morgan Stanley Healthcare Conference Date: Wednesday, September 16, 2026 Time: 1:05 p.m. ET Format: Fireside chat

Each fireside chat will be webcast live, and a replay may be accessed on the Investors section of the Gyre website where they will be archived for 30 days after the event.

About Gyre Therapeutics

Gyre Therapeutics is a commercial-stage biopharmaceutical company headquartered in San Diego, CA focused on the development and commercialization of small-molecule therapeutics with its most advanced programs addressing organ fibrosis and inflammatory diseases.

Gyre’s wholly-owned subsidiary, Cullgen Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader and DAC therapies for critical conditions including cancer and inflammatory diseases. Cullgen has created a portfolio of highly selective targeted protein degrader and DAC product candidates designed to potently and efficiently eliminate therapeutically relevant proteins in patients.

About Gyre Pharmaceuticals

Gyre Pharmaceuticals Co., Ltd., a subsidiary of Gyre Therapeutics, Inc., is a commercial-stage biopharmaceutical company committed to the research, development, manufacturing and commercialization of innovative drugs for organ fibrosis. Its flagship product, ETUARY™ (pirfenidone capsule), was the first approved treatment for IPF in the PRC in 2011 and has maintained a prominent market share over the past several years. In addition, Gyre Pharmaceuticals' pipeline includes F351 (hydronidone), a structural analogue of pirfenidone, which demonstrated statistically significant fibrosis regression after 52 weeks of treatment in a pivotal Phase 3 clinical trial in CHB-associated liver fibrosis in the PRC. In May 2026, China’s National Medical Products Administration (NMPA) accepted Gyre Pharmaceuticals’ New Drug Application (NDA) for F351 as a treatment for CHB-induced liver fibrosis, which is liver damage resulting from the infection of the hepatitis B virus (HBV). F351 received Breakthrough Therapy designation by the CDE of the NMPA in March 2021. Gyre Pharmaceuticals is also developing treatments for PD, RILI with or without immune-related pneumonitis, chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension (PAH) and acute/acute-on-chronic liver failure (ALF/ACLF). As of June 30, 2026, Gyre Therapeutics owns a 69.7% equity interest in Gyre Pharmaceuticals.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, are forward-looking statements, including statements concerning Gyre’s planned participation in the investor conferences described in this press release and the expected availability of live and archived webcasts. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our activities and actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks and uncertainties include, but are not limited to, changes to the timing, format or availability of the conferences and webcasts, as well as other risks and uncertainties identified under “Risk Factors” in Gyre’s Annual Report on Form 10-K for the year ended December 31, 2025 filed on March 13, 2026, and in other filings with the Securities and Exchange Commission.

Gyre expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Prompts

Gyre Therapeutics, Inc. (ticker GYRE), listed in United States.

Company History

Date Change Detail
Aug 3, 2023 Renamed CATALYST BIOSCIENCES, INC. → GYRE THERAPEUTICS, INC.
Jun 23, 2015 Renamed TARGACEPT INC → CATALYST BIOSCIENCES, INC.
— Former tickers CBIO

ETFs Holding Gyre Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
DFAS 0.00% 10,151 $ 43.649K Nov 12, 2026
AVSC 0.00% 1,907 $ 8,371.73 Nov 16, 2026